Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline of internally discovered and wholly owned cancer drugs. Iambic also has R&D alliances with companies such as Bayer and AbbVie.
The post AI Biotech Iambic Gets $150M in IPO Cash for ‘Molecular Superintelligence’ Drug R&D appeared first on MedCity News.
